Trial Profile
RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms RAPANK
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2019.
- 16 Aug 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.